BofA lowered the firm’s price target on Biogen to $260 from $280 and keeps a Neutral rating on the shares. For Q1, the firm’s estimates are below the Street for revenue and EPS as it expects steeper erosion for its core product portfolio, says the analyst, who also cites Leqembi’s slower than expected launch.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB: